S&P 500 Reaches New Heights: Analyzing the Factors Behind the Surge
The S&P 500 hits record highs, driven by options activity and a soft jobs report influencing market sentiment.
Ashland Inc. Explores Sale Amid M&A Buzz: Insights for Investors
Ashland Inc. is exploring a sale, raising questions about market dynamics and investor sentiment in the specialty chemicals sector.
S&P 500 Hits Record High Amid Options Surge: A Trader's Perspective
The S&P 500 reaches new heights fueled by options activity and a calm VIX, but is this rally sustainable?
Activist Moves: Rockstar Energy's Stake in Celsius Holdings Sparks Market Interest
Russ Savage's 4.7% stake in Celsius could reshape the company's future, signaling possible management changes.
Corning's Surge Signals Potential Record Highs for S&P 500
Corning's strong performance this week boosts market momentum, pushing the S&P 500 closer to record highs.
Market Moves: Atlassian's Earnings Surge and Homebuilder Consolidation
Atlassian's stellar earnings lift its stock, while Dream Finders Homes consolidates the market with a major acquisition.
July Jobs Report Disappoints: What It Means for US Markets
The July jobs report showcases a troubling trend for the US labor market, with implications for federal policies and market reactions.
Alkami Technology's M&A Potential: What Traders Need to Know
Alkami Technology's formal sale process sparks interest as traders eye potential M&A activity in the fintech sector.
Bank of America's Warning: Implications of the Situational Awareness Hedge Fund Collapse
Bank of America's CEO warns of systemic risks following the Situational Awareness hedge fund collapse, highlighting potential contagion in l…
ContextLogic's Bold Move: $850M Acquisition of gChem
ContextLogic is acquiring gChem for $850 million, marking a strategic shift into the chemicals sector.
Nasdaq 100 Surges: A Bullish Day for Traders
The Nasdaq 100 experienced a remarkable surge, marking one of its top 10 bullish days in the past decade.
Pfizer's Non-Covid Growth: A New Era for the Pharma Giant
Pfizer exceeds Q2 estimates, shifting focus from Covid to non-Covid products, indicating a new growth phase.